Drug Profile
Research programme: angiogenesis inhibitors - CGI Pharmaceuticals
Alternative Names: ASKA EphB4; Cancer therapeutics - CGI Pharmaceuticals; EphB4 inhibitors - CGI Pharmaceuticals; Multiplex angiogenesis inhibitors - CGI PharmaceuticalsLatest Information Update: 23 Sep 2010
Price :
$50
*
At a glance
- Originator CGI Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 25 Jul 2007 This programme is still in active development
- 10 Aug 2005 Cellular Genomics is now called CGI Pharmaceuticals
- 20 Jul 2005 CGI Pharmaceuticals has selected CGI 1842 as its lead candidate